Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

BrainStorm Tackles Neurodegenerative Diseases With Novel Cell Therapy

We recently took a detailed look at BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI). BrainStorm is a biotechnology company developing adult stem cell therapies for a range of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson's disease (PD), along with neurodevelopment disorders including autism. Below we give a brief overview of stem cells, BrainStorm's patented stem cell technology, and the application toward ALS before ending with an overview of our valuation.

Stem Cells - A Quick Background

Stem cells are distinguished from other types of cells in the body due to their unique characteristics: the capacity of self-renewal, their undifferentiated state, and their ability to differentiate into specialized cell types. These qualities make them especially attractive

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details